For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Eisai Subscribes to Incyte Genomics"Databases
April 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 23, 2001
- Mochida, Maruishi to Jointly Develop Capsaicin-based Cream
April 23, 2001
- Lilly's Gemzar Approved for Pancreatic Cancer Treatment
April 23, 2001
- Pharmacia's Zyvox Approved
April 23, 2001
- First Int'l GL for COPD Published
April 23, 2001
- GSK Obtains Import Approval for Alkeran for Injection 50mg
April 23, 2001
- Most Doctors Expect Effective Drugs Will Be Needed for AIDS in 2001: JHSF Survey
April 23, 2001
- Hisamitsu Forms Genofunctionfor Genome-related Business
April 23, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 23, 2001
- Keidanren, Nikkeiren to Discuss Healthcare System for Elderly
April 23, 2001
- WORLD NEWS IN BRIEF
April 23, 2001
- BUSINESS NEWS IN BRIEF -1-
April 23, 2001
- Hac Kimisawa to Open Record-high Number of New Stores
April 23, 2001
- BUSINESS NEWS IN BRIEF -2-
April 23, 2001
- Ain Pharmaciez, Nice Drug to Jointly Operate Large Dispensing Pharmacies in Tokai
April 23, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 23, 2001
- DIAGNOSTICS NEWS IN BRIEF
April 23, 2001
- NEW PRODUCTS NEWS IN BRIEF
April 23, 2001
- Kureha, Sankyo Tie Up for Joint Development of CXCR4 Blocker
April 23, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…